ACS Chemical NeuroscienceNeurosciencePeer-reviewed journal article
Synergistic Screening of Peptide-Based Biotechnological Drug Candidates for Neurodegenerative Diseases using Yeast Display and Phage Display
Cemile Elif ÖzçelikiD, Özge Beğli, Ahmet HınçeriD, Recep Erdem AhaniD, Mehmet Seçkin KesiciiD, Oğuzhan OğuziD, T. Serkan KasırgaiD, Salih ÖzçubukçuiD, Urartu Özgür Şafak ŞekeriD
Abstract
Peptide therapeutics are robust and promising molecules for treating diverse disease conditions. These molecules can be developed from naturally occurring or mimicking native peptides, through rational design and peptide libraries. We developed a new platform for the rapid screening of the peptide therapeutics for disease targets. In the course of the study, we aimed to employ our platform to screen a new generation of peptide therapeutics candidates against aggregation prone protein targets. Two peptide drug candidates for the protein aggregation prone diseases namely Parkinsons and Alzheimers diseases were screened. Currently, there are several therapeutic applications that are only effective in masking or slowing down symptom development. Nonetheless, different approaches are developed for inhibiting amyloid aggregation in the secondary nucleation phase, which is critical for amyloid fibril formation. Instead of targeting secondary nucleated protein structures, we tried to inhibit monomeric amyloid units as a novel approach for halting disease-condition. To achieve this, we combined yeast surface display and phage display library platforms. We expressed -synuclein, amyloid {beta}40, and amyloid {beta}42 on yeast surface, and we selected peptides by using phage display library. After iterative biopanning cycles optimized for yeast cells, several peptides were selected for interaction studies. All of the peptides have been used in vitro characterization methods which are QCM-D measurement, AFM imaging, and ThT assay, and they have yielded promising results in order to block fibrillization or interact with amyloid units as a sensor molecule candidate. Therefore, peptides are good choice for diverse disease-prone molecule inhibition particularly those inhibiting fibrillization. Additionally, these selected peptides can be used as drugs and sensors to detect disease quickly and halt disease progression. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=77 SRC="FIGDIR/small/536742v1_ufig1.gif" ALT="Figure 1"> View larger version (18K): org.highwire.dtl.DTLVardef@50c81dorg.highwire.dtl.DTLVardef@181fea5org.highwire.dtl.DTLVardef@17539c7org.highwire.dtl.DTLVardef@1244a00_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: yeast
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 8
- FWCI
- 1.41
- Field percentile
- top 20%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Using a stable protein scaffold to display peptides that bind to alpha-synuclein fibrils
Samuel Bismut, Matthias M. Schneider, … Janet R. Kumita·Protein SciencePeer-reviewed·May 15, 2025
- α-Helical peptidic scaffolds to target α-synuclein pathogenic species with high affinity and selectivity.
J. Santos, P. Gracia, … S. Ventura·bioRxiv·Mar 12, 2021
- In silico identification of novel peptides as potential modulators of Aβ42 Amyloidogenesis
Kavita Kundal, Santhosh Paramasivam, … Nandini Sarkar·bioRxiv·Apr 20, 2022
- AI-Guided Dual Strategy for Peptide Inhibitor Design Targeting Structural Polymorphs of α-Synuclein Fibrils
Jinfang Duan, Haoyu Zhang, Chuanqi Sun·CellsPeer-reviewed·Dec 3, 2025
- De novo Design of Peptides that Bind Specific Conformers of α-Synuclein
H. Wallace, H. Yang, … W. DeGrado·bioRxiv·Nov 14, 2023
- A peptide strategy for inhibiting different protein aggregation pathways in disease
T. Garfagnini, L. Ferrari, … A. Friedler·bioRxiv·Oct 22, 2022